Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 8 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Bellerophon Therapeutics, Inc. | 7,386,163 | reported | 17 Sept 2018 | tx 3+210,000 |
| KalVista Pharmaceuticals, Inc. | 5,012,796 | reported | 03 Feb 2025 | tx 3+70,023 |
| Oruka Therapeutics, Inc. | 4,148,428 | reported | 14 Feb 2025 | tx 5+122,882 |
| Altimmune, Inc. | 1,000,000 | reported | 25 Feb 2021 | tx 8+2,303,636−1,000,000 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 10 Feb 2025 | PURCHASE | Oruka Therapeutics, Inc. | 574 | 10.90 USD | |
| 14 Feb 2025 | PURCHASE | Oruka Therapeutics, Inc. | 88,794 | 11.44 USD | |
| 13 Feb 2025 | PURCHASE | Oruka Therapeutics, Inc. | 14,950 | 11.63 USD | |
| 12 Feb 2025 | PURCHASE | Oruka Therapeutics, Inc. | 8,971 | 11.86 USD | |
| 11 Feb 2025 | PURCHASE | Oruka Therapeutics, Inc. | 9,593 | 10.95 USD | |
| 31 Jan 2025 | PURCHASE | KalVista Pharmaceuticals, Inc. | 11,754 | 8.89 USD | |
| 30 Jan 2025 | PURCHASE | KalVista Pharmaceuticals, Inc. | 43,707 | 8.76 USD | first after silence |
| 03 Feb 2025 | PURCHASE | KalVista Pharmaceuticals, Inc. | 14,562 | 9.22 USD | |
| 25 Feb 2021 | OTHER | Altimmune, Inc. | 1,000,000 | 0.00 USD | |
| 25 Feb 2021 | OTHER | Altimmune, Inc. | 1,000,000 | 0.00 USD | deriv |
| 26 May 2020 | PURCHASE | Altimmune, Inc. | 390,547 | 9.78 USD | first after silence |
| 27 May 2020 | PURCHASE | Altimmune, Inc. | 125,162 | 7.23 USD | |
| 27 May 2020 | PURCHASE | Altimmune, Inc. | 277,000 | 7.92 USD | |
| 26 May 2020 | PURCHASE | Altimmune, Inc. | 309,453 | 8.79 USD | |
| 28 May 2020 | PURCHASE | Altimmune, Inc. | 173,711 | 8.87 USD | |
| 28 May 2020 | PURCHASE | Altimmune, Inc. | 27,763 | 7.79 USD | |
| 17 Sept 2018 | PURCHASE | Bellerophon Therapeutics, Inc. | 60,000 | 1.18 USD | |
| 14 Sept 2018 | PURCHASE | Bellerophon Therapeutics, Inc. | 75,000 | 1.23 USD | |
| 13 Sept 2018 | PURCHASE | Bellerophon Therapeutics, Inc. | 75,000 | 1.19 USD |
2 purchases reported after at least 12 months of silence — most recent on 30 Jan 2025.